Azucena García-Palacios Selected Research

Naltrexone (ReVia)

1/2022

Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost-utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Azucena García-Palacios Research Topics

Disease

3	Pain (Aches) 01/2022 - 01/2012
2	Fibromyalgia (Fibrositis) 01/2022 - 07/2018
2	Chronic Pain 10/2020 - 01/2020
2	Major Depressive Disorder (Major Depressive Disorders) 04/2019 - 01/2017
1	Borderline Personality Disorder (Personality Disorders, Borderline) 12/2021
1	Scoliosis 01/2021
1	Cancer Pain 01/2021
1	general anxiety disorder 01/2019
1	Postpartum Depression (Post-Natal Depression) 06/2018
1	Mental Disorders (Mental Disorder) 10/2015
1	Oppositional Defiant Disorder 01/2013

Drug/Important Bio-Agent (IBA)

1	Naltrexone (ReVia)FDA LinkGeneric 01/2022
1	SolutionsIBA 12/2019
1	mesoglycanIBA 04/2019

Therapy/Procedure

4	Therapeutics 06/2018 - 01/2013
2	Aftercare (After-Treatment) 12/2021 - 01/2019
2	Clinical Alarms 01/2021 - 01/2020
1	Braces 01/2021
1	Patient Care 10/2020
1	Pain Management 07/2018
1	Drug Therapy (Chemotherapy) 01/2012